Señales en vivo de CRDL.TO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 16:00):

Stats
Volumen de hoy	74 454.00
Volumen promedio	157 236
Capitalización de mercado	189.10M
EPS	$0 ( 2024-04-02 )
Próxima fecha de ganancias	( $-0.130 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.30
ATR14	$0.0110 (0.40%)

Volumen Correlación

Largo: 0.20 (neutral)

Corto: 0.85 (strong)

Signal:(60.883) Same movement expected

CARDIOL THERAPEUTICS INC Correlación

10 Correlaciones Más Positivas
AAX.V	0.802
ORL.TO	0.802

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CARDIOL THERAPEUTICS INC Correlación - Moneda/Commodity

-0.21
( neutral )

-0.23
( neutral )

0.00
( neutral )

-0.11
( neutral )

-0.52
( weak negative )

0.27
( neutral )

CARDIOL THERAPEUTICS INC Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-248 355 (0.00 %)
EPS:	$-0.440

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-248 355 (0.00 %)
EPS:	$-0.440

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-219 908 (0.00 %)
EPS:	$-0.180

FY	2021
Ingresos:	$78 760.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

CARDIOL THERAPEUTICS INC

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.